Detection significance of serum MAPK,VEGF and miR-532-3p in NSCLC patients with EGFR-TKIs resistance
Zhang Yuhe
Ma Huihui
Abstract：Objective To investigate the clinical significance of detecting serum levels of mitogen-activated protein kinase(MAPK),vascular endothelial growth factor(VEGF),and miR-532-3p in patients with EGFR-TKIs-resistant non-small cell lung cancer(NSCLC).Methods The clinical data of 80 patients with EGFR-TKIs-resistant NSCLC in the hospital from July 2018 to July 2023 were retrospectively analyzed and the patients were enrolled as observation group.The clinical data of 80 patients with non-resistant NSCLC during the same period were retrospectively analyzed and the patients were included in control group.The changes of serum MAPK,VEGF and miR-532-3p levels were compared between the two groups.Spearman method was used to analyze the correlation between serum MAPK,VEGF and miR-532-3p levels and staging of drug-resistant patients.According to the prognosis status of patients,the patients in observation group were divided into good prognosis subgroup and poor prognosis subgroup,and serum MAPK,VEGF and miR-532-3p levels were compared between the two subgroups.ROC curve was drawn to analyze the predictive efficiency of serum MAPK,VEGF and miR-532-3p levels on the prognosis in NSCLC patients with EGFR-TKIs resistance.Results In the observation group,the serum levels of MAPK,VEGF,and miR-532-3p were significantly higher compared to the control group(t=30.243,8.293,12.607,P<0.05),and these markers showed a positive correlation with TNM staging in the observation group(r=0.456,0.508,0.568,P<0.05).Serum levels of MAPK,VEGF and miR-532-3p in good prognosis subgroup were significantly lower than those in poor prognosis subgroup(t=11.117,9.854,24.101,P<0.05).The AUCs of serum MAPK,VEGF and miR-532-3p in predicting the prognosis in NSCLC patients with EGFR-TKIs resistance were 0.808,0.790 and 0.921 respectively(P<0.05).Conclusion Serum MAPK,VEGF and miR-532-3p are correlated with disease severity in patients with EGFR-TKIs-resistant NSCLC,and can be used as biological indicators to evaluate the prognosis.
Keywords：Epidermal growth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerMitogen-activated protein kinaseEndothelial growth factorMir-532-3p
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 27-30 )